RCC‐related studies showed that anti‐IL‐1β could participate in the formation of an immunostimulatory TME through multiple mechanisms, including remodeling the medullary compartment, reducing the infiltration of polymorphonuclear myeloid‐derived suppressor cells (MDSCs) in TME, inducing macrophages to polarize to M1‐type TAMs and promoting an increase in M1‐like tumor necrosis factor, and downregulating the expression of IL‐6, CXCL8 and other immunosuppressive cytokines, in which the decrease in CXCL8 may be the potential mechanism of inhibiting the recruitment of MDSCs.130, 131. The gene discussed is IL1B; the disease is renal cell carcinoma.